AstraZeneca and HUTCHMED said the Phase III SANOVO trial in 326 previously untreated patients with locally advanced or metastatic EGFR-mutated, MET-overexpressing NSCLC showed Tagrisso (osimertinib) plus Orpathys (savolitinib) significantly improved progression-free survival vs. Tagrisso alone. The first-line study also showed a “very encouraging” overall survival trend, with benefit reported in both the high-MET (IHC 3+) group and the broader intention-to-treat population.

Why It Matters To Oncology

• This is the combo’s third Phase III win and its first in the first-line setting, extending the case for dual EGFR/MET blockade beyond post-progression disease.

• The regimen targets a biologically relevant resistance pathway: co-occurring MET overexpression can limit the durability of EGFR-TKI monotherapy in treatment-naïve EGFR-mutated NSCLC.

• If confirmed in detailed data, the result could help define a biomarker-selected frontline option for a distinct subset of EGFR-mutated lung cancer.

The Financials

• For AstraZeneca, positive SANOVO data reinforce Tagrisso’s franchise strategy by expanding its role earlier in care and in combination use.

• For HUTCHMED, the readout could support regulatory submissions in China for first-line use of Orpathys with Tagrisso.

• The result also builds on prior commercial momentum: the combo was approved in China last year after the Phase III SACHI trial in the post-EGFR-TKI setting.

What They're Saying

• Lead investigator Yi-Long Wu said addressing EGFR and MET upfront with an all-oral, biomarker-directed regimen “offers a powerful new approach” and could reshape primary treatment strategy for this population.

• AstraZeneca oncology executive Leora Horn said the data add to evidence that Orpathys plus Tagrisso can intercept MET-driven resistance, delay progression and improve outcomes.

• The companies said safety in SANOVO was consistent with the known profiles of the two medicines, with no new safety findings reported.

What's Next

• Detailed SANOVO results will be presented at a future medical meeting and shared with regulators.

• Overall survival follow-up is ongoing, and mature OS data have not yet been disclosed.

• Clinicians will want hazard ratios, absolute PFS gains, subgroup detail by MET expression level, CNS outcomes and tolerability specifics before judging practice-changing potential.